Philadelphia, Pennsylvania 19104


Purpose:

The investigators aim to assess the influence of default options in advance directives on older patients selections of life- extending therapies and to determine whether alerting patients to the spectrum of possible default options in advance directives influences their selections of life-extending therapies by manipulating the default options of advance directives given to patients in with severe respiratory disease


Study summary:

The project is designed to document that default options influence terminally ill patients end-of-life decisions (in this case, adults with advance forms of lung disease) and that our team can recruit and retain patients in a study of advance care planning. In addition, because a larger-scale randomized clinical trial will require that the investigators alert participants to the range of possible default options, the investigators must also determine the effects that this alerting will have on their selections of life-extending therapies. Therefore, the investigators seek to achieve three aims: (1) assess the influence of default options in advance directives on patients selections of life-extending therapies; (2) determine whether alerting patients to the spectrum of possible default options in advance directives influences their selections of life extending therapies; and (3) document the feasibility of recruiting and retaining patients with advanced lung diseases from university-based clinical settings into a randomized trial of default options in advance directives.


Criteria:

Inclusion Criteria: - Diagnosis of chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), non-small-cell lung cancer, or other interstitial or fibrotic lung disease - Neither listed for nor considering solid organ transplantation - Anticipated survival of less than 2 years - Must be fluent and literate in English Exclusion Criteria: - Diagnosis of small-cell lung cancer or other respiratory diseases for which life extending medical therapies may be available


NCT ID:

NCT01346176


Primary Contact:

Principal Investigator
Scott D. Halpern, MD, PhD
University of Pennsylvania

Elizabeth Cooney, MPH
Phone: 215-573-9461
Email: elcooney@exchange.upenn.edu


Backup Contact:

Email: akray@mail.med.upenn.edu
Ashley Kraybill, BA


Location Contact:

Philadelphia, Pennsylvania 19104
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.